Page 18 - CIBERES2016-ENG

Chronic Respiratory Diseases Programme
Coordinator: Juan Fernando Masa Sleep line
a) We have a population of 70,000 patients with CPAP and a collection of samples of 550 patients for BigData analysis and clusters in SAOS; b) A commercial transfer has been generated which predicts the response to treatment based on biomarkers (HIPARCO-Score); c) In SAOS manipulation, 5 publications have been obtained and 5 studies completed; d) A virtual sleep unit has been got under way and a platform for monitoring patients with SAOS, generating 5 publications; e) 16 articles have been published on the SAOS-cancer relationship, intermittent hypoxia being responsible for the increase in tumor incidence; f) 3 papers have been given at congresses on the SAOS- Alzheimer relationship and there are 3 projects under way; and g) The SAOS-cardiovascular relationship has been explored, generating 7 articles, one at the NEJM.
COPD line
Progress has been made in the cohorts of the line (DELICATO-BIOMEPOC, EARLY-EPOC and PESA-CNIC) and in the following activity biomarkers: a) Transcriptome analysis of the DELICATO-BIOMEPOC cohort, now
in the biostatistical analysis stage; b) Analysis of networks displaying the participation of B lymphocytes
in serious emphysema; c) Microbiome: definition of the microbiome by analysis of 16S-rRNA. Adaptive traits of the virulence of NTHi identified. Cover of anti-pneumococcal vaccine PCV13 in COPD defined; d) Biomarkers of systemic inflammation connected with exacerbation of COPD defined; e) Identification of individuals with poor pulmonary development having lower development and more comorbidities; and f) Experimental treatments: progress in treatment of emphysema with LGF and guanylate cyclase.
Asthma Line
a) Starting a multicentre study to determine the events giving rise to an asthmatic population, long-term parameters which may determine changes in patients’ severity and what treatments are of influence in the progression of asthma, the causes of exacerbations and how these affect asthma’s evolution; b) A cohort of 450 patients has been got under way with 250 already included. The first results have been sent to SEPAR and ERS. Financing for the project has been obtained from the FIS (PI15/01900) (140,000 €) and from SANOFI (120,000 €); and c) In 2016 the members of the group took part in 31 publications, 12 international and 19 national.
Cancer Line
a) Cohorts (IASLC, CIBERES and Early-COPD) of patients with LC in the Ip/IIp stages: the inflammatory and tumour stroma biomarkers are associated with a bad prognosis and there is an overexpression of miARNs in patients with prolonged survival; b) 207 patients with lung cancer in more advanced early stage (FIS grant), had a greater CRP and TNF-2 receptor. An associated project (SEPAR) has produced two publications; c) The results of a screening cohort using low doses of CT (LD-CT) (>500 individuals) have been presented at national congresses and ATS 2017; d) The recruiting of patients with lung cancer diagnosed/staged by EBUS-TBNA started; e) In the LC cohort (>200 subjects) and in 50 patients with lung cancer a high prevalence of sleep-related breathing disorders was found. The results are presented in SEPAR, ERS and ATS.
18